

Made in the UK



# THE HEXI FAMILY

Making skin & site care simple, helping to reduce bloodstream infections and false-positive blood culture results

 $\odot$ 

High-quality, efficacious products powered by 2% chlorhexidine in 70% alcohol



Compliant with epic3, NICE and Infusion Therapy Standards of Practice guidance<sup>1,2,3</sup>



Solutions for initial skin disinfection, ongoing IV site maintenance and blood culture collection



# The ultimate defence against infection



Due to the risk of surgical wound infections, the Association of peri-Operative Registered Nurses (AORN) guidelines<sup>4</sup> suggest that skin antispetic products used prior to an invasive procedure, should be sterile. The Royal College of Surgeons and the MHRA recommend the use of a licensed medicine containing CHG to prepare the skin prior to surgery<sup>5</sup>.

HEXI PREP, manufactured through a patented process, is the world's first sterile pharmaceutical licensed 2% chlorhexidine in 70% alcohol wipe. Allowing you to easily conform to the AORN guidelines<sup>4</sup> of using a sterile product prior to invasive procedures.

The sterility of HEXI PREP is crucial in minimising the risk of infection at the point of entry, providing an added layer of safety and aligning with the AORN and RCS/MHRA recommendations<sup>4,5</sup>.

## Advantages of HEXI PREP

### COST-EFFECTIVE CARE

HEXI PREP's glass-free compact presentation focuses on reduced plastic, packaging, and volume of waste thus assisting in reducing the Trust's waste management burden. HEXI PREP's size supports access at point of care and compliance.

### STAY COMPLIANT

HEXI PREP is a clinically proven licensed pharmaceutical. It facilitates compliance with epic3 guidelines and maintains effective aseptic practice during application<sup>1</sup>. IVAD15 recommends using 2% chlorhexidine digluconate in 70% isopropyl alcohol to disinfect areas of a patient's skin before inserting a peripheral vascular access device<sup>1</sup>.

### STRAIGHT FORWARD SKIN DISINFECTION

HEXI PREP's **'apply & dry'**, skin disinfection pad can be used readily and intuitively with standard ANTT approach<sup>6</sup>. HEXI PREP's fast dry time and long-lasting residual protection<sup>7</sup> make it suitable for many different types of vascular access procedures.











# **Device disinfection**

HEXI HUB is a class IIa disinfectant wipe designed for the disinfection of non-invasive medical devices, such as catheter hubs, access ports and needleless connectors as well as the tops of blood culture collection bottles.



### PROVEN REDUCTION

Proven to reduce catheter related blood stream infections by 75%<sup>12</sup>.



# Instructions for use



#### For initial insertion:

Keep the impregnated pad folded and press firmly against the skin on the intended area and wipe back and forth for a total of 30 seconds<sup>7</sup> to ensure thorough decontamination of the skin before medical procedures, such as peripheral venous and arterial cannulation, simple biopsies, routine venepuncture and cleansing at dialysis fistula/graft sites.

#### For ongoing maintenance:

Beyond insertion, HEXI PREP is essential for the daily or routine cleansing of all catheter insertion sites, supporting dressing changes and the overall maintenance of the IV site to prevent infection.

#### For blood culture collection:

Keep the impregnated pad folded and press firmly against the skin on the intended area and wipe back and forth for a total of 30 seconds to ensure thorough decontamination of the skin. This sterile application is crucial for effectively minimising blood culture contamination.





#### For ongoing maintenance:

Utilise HEXI HUB consistently for the routine disinfection of any catheter hub, access port, or needleless connector. Scrub the hub for a minimum of 10 seconds<sup>13</sup>.

### For blood culture collection:

HEXI HUB is recommended for scrubbing the top of the blood culture bottles for at least 10 seconds before blood insertion to uphold sample integrity and prevent microbial contamination.



# Order information

PRODUCT	PRODUCT CODE	NHSSC CODE	UNIT OF ISSUE	PAD SIZE
HEXI PREP 1.5ml	CHEX15	DMK004	Box of 100 sachets	100 x 100 mm
HEXI PREP 3.0ml	CHEX30	DMK003	Box of 50 sachets	100 x 100 mm
HEXI HUB	CA2C240	VJT638	Box of 240 wipes	-

Prescribing information: HEXI PREP 2% w/v / 70% v/v for cutaneous use. Refer to Summary of Product Characteristics before prescribing. Presentation: Each impregnated pad contains 1.5 ml or 3.0 ml of 20 mg chlorhexidine digluconate and 0.7 ml of isopropyl alcohol. Indication: Disinfection of the skin prior to invasive medical procedures that do not require a clean air environment. Dosage & administration: There are two pad sizes available. HEXI PREP may be used on all age groups and patient populations. Use with care in newborn babies, especially those born prematurely. The choice of pad size will depend on the size of the area to be disinfected, the invasive procedure and the clinician's preference. For both non-sterile and sterile procedures, the user should wear gloves during application. Keep the pad folded and press firmly against the skin on the intended area and wipe back and forth for a total of 30 seconds. Allow to air dry completely. It is recommended that HEXI PREP solution remains on the skin post-procedure to provide continued antimicrobial activity. If removal is necessary, remove with soap and water or alcohol. Contraindications: The medicinal product is contraindicated where patients have shown previous hypersensitivity to chlorhexidine or isopropyl alcohol. Warnings & precautions: The solution is flammable. Do not use with electrocautery procedures or other ignition sources until dry. Remove any soaked materials, drapes or gowns before proceeding with the intervention. Do not allow the solution to pool in skin folds or under the patient or drip onto sheets or other material in direct contact with the patient. Where occlusive dressings are to be applied to areas previously exposed to HEXI PREP, care must be taken to ensure no excess product is present prior to application of the dressing. For external use only on intact skin. Do not use on open skin wounds. Avoid prolonged contact with the skin. Do not use on broken or damaged skin. Avoid contact with neural tissue, the middle ear, the eyes and mucous membranes. Chlorhexidine-containing products are known causes of anaphylactic reactions during anaesthesia. The symptoms of anaphylactic reactions might be masked in an anaesthetised patient. If symptoms of an anaphylactic reaction are detected during anaesthesia, chlorhexidine-related allergic reactions should be considered. When chlorhexidinerelated reaction during anaesthesia is suspected, other products containing chlorhexidine used during anaesthesia (e.g. IV lines) should be removed. Special precaution should be taken to avoid patient exposure to any other product containing chlorhexidine during the course of the treatment. The use of chlorhexidine solutions, both alcohol based and aqueous, for skin antisepsis prior to invasive medical procedures has been associated with chemical burns in neonates. Based on available case reports and the published literature, this risk appears to be higher in preterm infants, especially those born before 32 weeks of gestation and within the first 2 weeks of life. Pregnancy & lactation: There are no studies with this product in pregnant or lactating women. No effects during pregnancy are anticipated since systemic exposure to chlorhexidine digluconate is negligible. HEXI PREP can be used during pregnancy. No effects on the breastfed newborn infant are anticipated since the systemic exposure of breast-feeding women to chlorhexidine digluconate is negligible. HEXI PREP can be used during lactation. Undesirable effects: Skin disorders: very rare allergic or irritation skin reactions have been reported with chlorhexidine and isopropylalcohol: erythema, rash (e.g. erythematous, papular, or maculopapular), pruritus and blisters or application site vesicles. Other local symptoms have included skin burning sensation, pain and inflammation. Frequency not known: dermatitis, eczema, urticaria, chemical burns in neonates. Immune disorders: Frequency unknown: Hypersensitivity including anaphylactic shock. Cases of anaphylactic reactions have been reported during anaethesia. Common reported reactions: associated with site reactions often within the area of application and very rarely spread. This product may cause a severe allergic reaction. Symptoms may include wheezing / difficulty breathing, shock, facial swelling, hives or rash. Use of HEXI PREP is contraindicated where patients have shown previous hypersensitivity to chlorhexidine or isopropyl alcohol. If hypersensitivity or an allergic reaction occurs, stop use and seek medical help right away. Reporting adverse events: Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GAMA Healthcare Ltd. Per pad costs (NHS Supply Chain; ex VAT): HEXI PREP(CHEX15) 1.5 ml UK £0.28, HEXI PREP (CHEX30) 3.0 ml UK £0.66. Legal category: UK GSL. Marketing Authorisation Numbers: HEXI PREP (PL 40867/0002). Marketing Authorisation Holder: GAMA Healthcare Ltd., Maylands Building, Maylands Avenue, Hemel Hempstead Industrial Estate, Hemel Hempstead, Hertfordshire, HP2 7TG. Date of issue: May 2023.

**HEXI PREP** and **HEXI HUB** are designed and developed by infection prevention specialists and creators of Clinell Universal Wipes, GAMA Healthcare.

For more information on us, visit www.gamahealthcare.com

### References

- Loveday HP, Wilson JA, Pratt RJ, et al. epic3: national evidencebased guidelines for preventing healthcare-associated infections in NHS hospitals in England. J Hosp Infect. 2014;86 Suppl 1:S1-S70. doi:10.1016/S0195-6701(13)60012-2
- National Institute for Health and Care Excellence. Healthcareassociated infections: prevention and control in primary and community care. Published March 28, 2012. Accessed April 18, 2024. https://www.nice.org.uk/guid ance/cg139
- Nickel B, Gorski L, Kleidon T, et al. Infusion Therapy Standards of Practice, 9th Edition. *J Infus Nurs*. 2024;47(15 Suppl 1):S1-S285. doi:10.1097/NAN.00000000000532.
- Association of peri-Operative Registered Nurses (AORN). Standards, Recommended Practices and Guidelines. 1st Edition. Denver: AORN, 2006.
- Royal College of Surgeons of England. Joint RCS/MHRA Statement on use of Topical Chlorhexidine for Skin Preparation Prior to Surgery. https://www.rcseng.ac.uk/about-the-rcs/government-relations-andconsultation/joint-rcs-mhra-statement-on-use-of-tropical-chlorhexidinefor-skin-prep/#:~:text=Statement%20on%20the%20use%20of,to%20 prevent%20surgical%20site%20infection. Accessed on May 7, 2024.
- Aseptic Non-Touch Technique (ANTT). ANTT Procedure Guidelines. https://www.antt.org/antt-procedure-guidelines.html. Accessed May 7, 2024.
- 7. HEXI PREP Skin disinfection, Summary of Product Characteristics, 2021.

- Hong H, Morrow DF, Sandora TJ, Priebe GP. Disinfection of needleless connectors with chlorhexidine-alcohol provides long-lasting residual disinfectant activity. *Am J Infect Control.* 2013; 41(8):e77-e79. doi:10.1016/j.ajic.2012.10.018
- Moureau NL, Flynn J. Disinfection of Needleless Connector Hubs: Clinical Evidence Systematic Review. Nurs Res Pract. 2015:796762. doi:10.1155/2015/796762
- Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. *Lancet*. 1991;338(8763):339-343. doi:10.1016/0140-6736(91)90479-9
- Mimoz O, Pieroni L, Lawrence C, et al. Prospective, randomized trial of two antiseptic solutions for prevention of central venous or arterial catheter colonization and infection in intensive care unit patients. *Crit Care Med.* 1996;24(11):1818-1823. doi:10.1097/00003246-199611000-00010
- Soothill JS, Bravery K, Ho A, Macqueen S, Collins J, Lock P. A fall in bloodstream infections followed a change to 2% chlorhexidine in 70% isopropanol for catheter connection antisepsis: a pediatric single center before/after study on a hemopoietic stem cell transplant ward. *Am J Infect Control.* 2009;37(8):626-630. doi:10.1016/j.ajic.2009.03.014
- 13. Laboratory BS EN 16615 Efficacy Report M 2024\_001. 2024.

CE 0050 Class Ila Medical Device

Check manufacturer's guidelines before cleaning equipment with this product.

